CD274 and esophageal cancer: Similarly, KEYNOTE‐18133 showed that pembrolizumab prolonged OS versus chemotherapy as second‐line therapy for advanced esophageal cancer in patients with PD‐L1 CPS ≥10 (median, 9.3 vs. 6.7 months; HR, 0.69, p = 0.0074).